로딩 중…
지수 로딩 중…
HLB Pep Co., Ltd.
196300· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,150-0.72%
2026-09-18
Financials
Valuation Metrics
HLB Pep Co., Ltd.'s Market Cap is ₩394B. At end of 2025 it was ₩680B. Ranked #1910 of 2,421 in KR market (top 79%), #1190 of 1,640 on KOSDAQ (top 73%), #204 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 39.40B KRW | KR#1,910/2,421 Sec#204/231 |
| Revenue | 5.54B KRW | KR#2,334/2,421 Sec#191/231 |
| Net Income | -3.19B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 49.67B KRW | KR#2,210/2,421 Sec#200/231 |
| Net Assets | 23.01B KRW | KR#2,254/2,421 Sec#209/231 |
| Employees | 83 | KR#1,786/2,421 Sec#147/231 |
| Value | ||
| P/B | 1.71x | KR#1,845/2,421 Sec#134/231 |
| P/S | 7.11x | KR#2,218/2,421 Sec#153/231 |
| FCF Yield | -27.22% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -13.86% | KR#2,003/2,421 Sec#153/231 |
| ROA | -6.42% | KR#1,992/2,421 Sec#146/231 |
| Op. Margin | -140.45% | KR#2,322/2,421 Sec#181/231 |
| Revenue Growth | 14.70% | KR#701/2,421 Sec#68/231 |
| Financial Health | ||
| Debt Ratio | 115.87% | KR#1,686/2,421 Sec#192/231 |
| Total Debt | 17.23B KRW | KR#1,431/2,421 Sec#117/231 |
| FCF | -10.72B KRW | KR#1,727/2,421 Sec#151/231 |
| Cash | 1.22B KRW | KR#2,321/2,421 Sec#219/231 |
| Current Ratio | 1.22x | KR#1,487/2,421 Sec#154/231 |
| Performance | ||
| 1Y Return | -43.92% | KR#1,925/2,421 Sec#164/231 |
| 1M Return | -12.54% | KR#2,181/2,421 Sec#182/231 |
| From 52W High | -56.45% | KR#1,719/2,421 Sec#131/231 |
| 1Y MDD | -60.48% | KR#1,504/2,421 Sec#122/231 |
| Trading | ||
| Volume | 922 shares | KR#2,331/2,421 Sec#225/231 |
| Trading Value | 3.8M KRW | KR#2,345/2,421 Sec#223/231 |
| Foreign Own. | 1.11% | KR#1,993/2,421 Sec#195/231 |
| Per Share | ||
| EPS | -336 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,424 KRW | KR#1,974/2,421 Sec#158/231 |
Company Info
동사는 2000년 펩타이드 바이오소재 및 글로벌 혁신 신약 개발 회사로 설립됨. 의약품, 원료의약품, 의약부외품 제조·판매 및 생명공학 관련 연구개발업을 영위하며, 의약용 펩타이드 소재 40.36%, 연구용 펩타이드 소재 54.93%의 매출 비중을 보임. APsoluT 플랫폼 기술로 유방암, 위암, 대장암 신약 후보 발굴 및 네트워킹을 통한 연구개발 진행하고 있음. HLB펩는 2000년에 설립되었으며 광주광역시 북구에 본사를 두고 있습니다.